NCT06220552View on ClinicalTrials.gov

The Efficacy and Safety of Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Glioblastoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 27, 2023

Primary Completion Date

December 30, 2027

Study Completion Date

December 30, 2027

Conditions
Recurrent Glioblastoma
Interventions
DRUG

Sintilimab

Sintilimab 200mg D1, Q3W

RADIATION

Low-dose Radiotherapy

Radiotherapy 1Gy/1F, D1/D2/D8/D15, Q3W

Trial Locations (1)

519000

RECRUITING

Yingpeng Peng, Zhuhai

All Listed Sponsors
lead

Fifth Affiliated Hospital, Sun Yat-Sen University

OTHER